Affordable Access

Publisher Website

Special considerations for carvedilol use in heart failure

Authors
Journal
The American Journal of Cardiology
0002-9149
Publisher
Elsevier
Publication Date
Volume
93
Issue
9
Identifiers
DOI: 10.1016/j.amjcard.2004.01.028
Disciplines
  • Biology
  • Medicine
  • Pharmacology

Abstract

Abstract Remarkable improvements in morbidity and mortality caused by heart failure have been realized because of a greater understanding of the pathobiologic mechanisms of left ventricular dysfunction and the subsequent application of neurohormonal antagonism to the heart failure milieu. The median survival of patients with chronic heart failure has greatly increased with the use of effective medical therapy that includes angiotensin-converting enzyme inhibitors and β-blockers, especially carvedilol. Still to be addressed is the issue of clinical trials that underrepresent special populations of patients who are affected with heart failure (eg, the elderly, women, and African Americans). Even though heart failure may be a somewhat different illness in etiology, epidemiology, or responsiveness to medical therapy for each of these groups, it is of utmost importance that patients affected by heart failure be treated with agents that have been shown to be of benefit in the major controlled clinical trials in heart failure.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Carvedilol use in heart failure.

on The Annals of Pharmacotherapy March 1998

Use of carvedilol in the treatment of heart failur...

on Hospital medicine (London, Eng... May 2003

The use of carvedilol in pediatric heart failure.

on Cardiovascular & hematological... March 2006

Carvedilol: use in chronic heart failure.

on Expert Review of Cardiovascula... January 2007
More articles like this..